Evgen Pharma Share Discussion Threads

[hodhasharon] 04/3/2021 12:32

on IG they were straight in there. Same day.

[moneymunch] 04/3/2021 12:22

Hopefully so HH, this should pick up steam as the placing dust settles and i wouldn't be surprised if Huw has an update or two to report this coming week, although i'm still waiting for my account to be updated on allocation as well as additional. ;-)

[hodhasharon] 04/3/2021 12:09

Fingers crossed MM....I think that was the bottom.

[moneymunch] 04/3/2021 12:07

Cheers awaise355, Evgen looks like a very attractive investment opportunity now that they're fully funded for the forseeable with so many shots on so many targets, and look forward to plenty of positive material newsflow from Huw in the coming days and weeks to drive the share price to new highs. Gl ;-)

[awise355] 04/3/2021 11:26

That's a great post thank you

[markth126] 03/3/2021 18:12

Mines all gone through yesterday now hope it's soon

[dutch123] 03/3/2021 16:30

Plus Huw and Sue topped up with the placing.

[moneymunch] 03/3/2021 14:08

Exciting times ahead from a fully funded Evgen, in anticipation of a flow of positive news from Huw in the coming days, weeks and months. Gla ;-)

Commenting on the Fundraising, Huw Jones, CEO of Evgen Pharma plc, said:

"This heavily oversubscribed fundraising is transformative for us and allows us to accelerate both our future clinical and current pre-clinical work dramatically, together with expanding our senior management team to support our growth. We are very pleased with recent progress of our work on SFX-01 and are most grateful for the support shown in this placing by existing shareholders. The Placing also brings a number of new, high quality shareholders to our register and we offer a warm welcome to them as we accelerate our progress in a range of cancers and acute respiratory distress."

[dutch123] 03/3/2021 13:06

Tomorrow will be a better day.

[bumpa33] 03/3/2021 12:51

good to get that out of the way, though who gets stock at 8 only to sell it here I’ll never know - idiots.

[dutch123] 03/3/2021 12:36

All duly passed. o.a.u.

[ewanwhose] 03/3/2021 10:10

There are ways of getting coins without pestering Nobby!

[ships250] 03/3/2021 10:07

Hi nobby, could I have a coin for the guild please. Many thanks

[moneymunch] 03/3/2021 07:02

3 March 2021

Evgen Pharma plc

("Evgen Pharma" or "the Company")



Result of Open Offer



Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, is pleased to announce the results of its Open Offer.

On 2 February 2021, Evgen announced its intention to raise gross proceeds of up to £11 million by way of a Placing and Open Offer, all at an issue price of 8 pence per New Ordinary Share. A total of 137,490,676 New Ordinary Shares will be issued at the Issue Price (subject to the conditions noted below), of which, 12,490,676 New Ordinary Shares will be issued pursuant to the Open Offer. This brings the gross proceeds of the Fundraising to approximately £11 million before expenses.

The Open Offer closed for acceptances at 11.00 a.m. yesterday. The Company has received valid acceptances from Qualifying Shareholders in respect of their Basic Entitlements in respect of 5,389,931 New Ordinary Shares, representing approximately 43 per cent. of the Open Offer Shares. In addition, the Company has received applications from Qualifying Shareholders under the Excess Application Facility in respect of 14,359,431 New Ordinary Shares, representing a total over-subscription of approximately 58 per cent. of the available Open Offer Shares. Accordingly, Qualifying Shareholders who have validly applied for Open Offer Shares will receive their full Basic Entitlements. As applications under the Excess Application Facility cannot be satisfied in full, applications for New Ordinary Shares under the Excess Application Facility will be scaled back in accordance with the terms set out in the Circular.

General Meeting

The Fundraising remains conditional on the approval by Shareholders of the Resolutions at the Company's General Meeting to be held at 10:00 a.m. today (or any adjournment thereof), the satisfaction of certain conditions in the Placing Agreement and Admission of the New Ordinary Shares to trading on AIM occurring at or before 8.00 a.m. on 4 March 2021 (or such later date as the Company and finnCap may agree, being not later than 8.00 a.m. on 18 March 2021).

The Company will announce the results of the General Meeting as soon as practicable after the meeting concludes.

[kingalf] 02/3/2021 20:28

I'm holding out for 6.65p, that is a long term support line stretching back to June 2016

[moneymunch] 02/3/2021 18:35

James D Chalmers

@ProfJDChalmers

·

23m

Join us on Thursday evening for the release of the

@EuroRespSoc

#COVID19 treatment guidelines for hospitalized patients. An interactive webinar reviewing the latest evidence on COVID19 treatment

[markth126] 02/3/2021 18:05

I think a lot of that has gone on this week but I have added significantly at between 8-9p very happy to see the pipeline unfold over coming months

[riggerbeautz] 02/3/2021 17:45

Good way to bring your average down if you don’t want to increase your holding. Sell whatever you know are getting held higher, keeping your position the same; seems fairly sensible to me.

[moneymunch] 02/3/2021 17:42

It's going to get a great deal better very soon imho....Gl ;-)

ps did someone pick up 1.2m shares on the cheap???

[moneymunch] 02/3/2021 15:50

6. Conclusions

In summary, there is mounting supporting evidence that SFN may have therapeutic potential in kidney disease by stimulating the NRF2 pathway (Figure 2). SFN is currently in clinical trials for cancer of the breast, lung, and prostate, as well as autism and schizophrenia (Clinicaltrials.gov). However, currently no clinical study has been performed to assess the effect of SFN in CKD. As SFN and its metabolites are cleared by the kidney [144], safety and efficacy should first be established in patients with kidney disease, particularly in those with more advanced stages of CKD. Once established, large, randomized, placebo-controlled trials are needed to determine the effect of SFN on long-term outcomes such as disease progression and mortality in patients with CKD, and whether the effect is modified by genetics in a precision medicine approach.